Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States (vol 6, 100252, 2021)ESMO OPENIF8.32021-12-011OAAI
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United StatesESMO OPENIF8.32021-10-0136OAAI
未登录.png){kind=icon}
未登录
